Survey among healthcare professionals (neurologists treating patients with MS along with MS specialist nurses) and patients in selected European countries plus Canada to evaluate the knowledge required for the safe use of Mayzent (siponimod)

Study type

• Study type:
  Non-interventional study
• Scope of the study:
  Assessment of risk minimisation measure implementation or effectiveness
• Data collection methods:
  Primary data collection

Non-interventional study

• Non-interventional study design:
  Other
• Non-interventional study design, other:
  Multinational, questionnaire-based, cross-sectional survey to be conducted among 1) healthcare professionals and 2) patients/caregivers

Study drug and medical condition

• Name of medicine:
  MAYZENT
• Study drug International non-proprietary name (INN) or common name:
  SIPONIMOD
• Anatomical Therapeutic Chemical (ATC) code:
  (L04) IMMUNOSUPPRESSANTS

  IMMUNOSUPPRESSANTS
• Medical condition to be studied:
  Multiple sclerosis

Population studied

• Age groups:
  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)
• Estimated number of subjects:
  335

Study design details

• Main study objective:
  The objective of this survey is to evaluate whether HCPs and patients/caregivers receive the educational materials and to capture their knowledge of specific Mayzent (siponimod) safety measures.
• Data analysis plan:
  The analysis will be descriptive in nature. For continuous variables, counts, means (with standard deviations), medians and ranges will be provided. For categorical variables, frequencies and percentages (with 95% confidence intervals) will be provided. Missing data will be noted for each variable.